chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This spontaneous report was received from a pharmacy intern and refers to a female patient of unknown age. No information regarding the patient's medical history, concurrent conditions and concomitant medications was provided. On 28-AUG-2017 (reported as "2-3 weeks ago"), the patient was vaccinated with a dose of ZOSTAVAX (strength, route of administration, lot# and expiration date were not provided) for prophylaxis. Concomitant therapies included sterile diluent. On an unknown date in 2017, the patient experienced elbow joint pain. The patient has not gone to a physician yet and has not taken any medicine for the event. The reporter additionally asked, if the patient could receive a flu vaccine. The outcome of the event and the causal relationship between the event and ZOSTAVAX was not provided.
entire arm and hand swelling and turning red and itching. Started about 12 hours after receiving the vaccine and continued 48-72 hours after.  Did not seek medical care as had the same type of reaction after the second covid vaccine and the doctor told her to take Benadryl around the clock.
Initially - localized discomfort. Redness days after - swelling at sign of injection, fatigue, strong stomach pain on 1-6-21 further discomfort and swelling two inches distal of injection site.
Menstrual period started 13 days early. Significantly heavy flow and twice the normal cycle length at time of reporting (still ongoing bleeding).
Fever at injection site, fever overall, extreme back pain, severe muscle cramps, may have contributed to a cardiac arrythmitia that caused difibrulator to deliver a shock.
Pt recv vax on 3/12/99; 10 min post vax pt exp flushing, giant urticaria, sneezing; tx=Benadryl, Prelone, Medrol Dosepak
5/5/21: "Good morning sorry to bother you had a question about this shot (Janssen Covid19 vaccine). I have been checking in with that website (V-safe App)  you gave me no one has contacted me. Monday (5/3/21) I missed work due to me not feeling good and still today (5/5/21) I'm at work but feel like I could fall asleep, no energy, nausea still, and like I haven't slept in weeks even though I get good sleep. My breathing has gotten to the point that it hurts to take a deep breath. I believe this is all due to the shot but didn't know what you thought."
got sick / didn't feel good; This case was reported by a pharmacist via call center representative and described the occurrence of sickness in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, immediately after receiving Shingrix, the patient experienced sickness. The patient was treated with methylprednisolone (Medrol Dosepak). On an unknown date, the outcome of the sickness was unknown.   It was unknown if the reporter considered the sickness to be related to Shingrix.  Additional details were provided as follows: The age group was not reported, however it was captured as an adult as per vaccine indication. The age at vaccination was not reported. The patient got sick and did not feel good right after receiving the first dose of Shingrix. The patient was given Medrol Dosepak. No additional details were available. The reporter did not consent to follow up. The reporter could not clarify further what got sick entailed and did not remember any further details. The reporter does not wish to be contacted because she had nothing more to provide.
Post 7 hours ... Sore arm...then the rest hit with a vengeance.... chills/fever Total body aches Nausea/vomiting 10x worse than my symptoms of covid which were actually pretty intense.
Patient reports rash on forearms (side and radiation to underside of forearms when holding arms out in front of her with palms up). Reports rash looks like mosquito bites, and complains of itching. No other reaction.
syncope like reaction occuring about 15 minutes after vaccine given- patient was incoherent for few minutes and very weak, sweaty and pale- ambulance was called and patient taken to hospital
Information has been received from a pharmacist concerning two patients who on an unknown date were vaccinated with a dose of ZOSTAVAX (Merck) (lot # not provided) for prevention of shingles. Subsequently, after receiving the vaccine the patients experienced rashes around the injection site. The patients sought pharmacist attention. Follow up information received on 07-MAY-2007 from the pharmacist stated that the patient was vaccinated on 21-APR-2009 with a dose of ZOSTAVAX (Merck) (lot # 664091/0140Y). This is one of two reports from the same source. Additional information has been requested.
pt recvd vax & exp itching upper chest; The next day had red patchy area (upper chest) for two days; pt was seen by MD; sx subsided;
he had a sore arm after his vaccine; Rash; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 72 year-old male patient received bnt162b2 (BNT162B2), administered in arm, administration date 05Feb2021 (Lot number: EM9809) as dose 2, single and administered in arm right, administration date 15Jan2021 (Lot number: EL3302) as dose 1, single for covid-19 immunisation. The patient's relevant medical history was not reported. There were no concomitant medications. The following information was reported: PAIN IN EXTREMITY (non-serious), outcome "recovered", described as "he had a sore arm after his vaccine"; RASH (non-serious) with onset Aug2021, outcome "not recovered", described as "Rash". Therapeutic measures were not taken as a result of pain in extremity. Therapeutic measures were taken as a result of rash.  Additional Information: The patient stated that this was with both doses. The patient stated that with first dose that it was so sore that he was unable to lay on his arm. The patient stated that with the second dose that he could lay on his arm. The patient stated that the it was the right arm with the first dose. The patient stated that it was unknown arm with second dose. Treatment received for event rash by aspirin, Diclofenac Sodium, Topical gel 1% to rub on it.  No follow-up attempts are possible. No further information is expected.
Patient developed abd pain/bilious vomiting 5 wks post vaccine dx intussusception which was reduced without complication.
pt recv vax 30SEP96 & devel redness & warmth @ the inj site the same day;outcome is unk;this case was reported by a RN;cross reference w/ 010150960051/54;
Within a couple hours of the second dose my tinnitus exploded and got extremely loud.  It has continued to be very loud.  Also Followed by a continued fogginess and occasional dull headache.
Healthy no current illnesses.  Had stage 1 uterine cancer April 2021. Scans post hysterectomy negative for cancer was in readmission. Scan November 11, 2021 metastatic uterine cancer to upper abdomen.  Patient notified results  11/22/21. Gynecologist oncologist would refer to MD for treatment plan. 12/2/21 gynecologist oncologist reviewed plan with patient and refer to hematologist oncologist to manage chemo. Port placement scheduled for 12/16/21. Hematologist oncologist appt on 12/14/21 discusses hospitalization for AIM regimen chemo and to start chemo after holiday.  On 12/15/21 patient taken to emergency room by son due to lower abdominal pain and patient suspected appendicitis. Patient cancer  metastasized to lower right and and other scattered areas through abdomen. Patient admitted and port placed as planned next day 12/16/21.   Chemo initiated 12/16/21-12/20/21. 1/6/22 re admitted for second round chemo. Patient swabbed positive COVID 19. Pt discharged home 1/10/22 on home oxygen 2 Lpm.  1/12/22 patient readmitted for increase O2 need 15-20 Lpm. Patient dc home/hospice 1/26/22 patient deceased 1/27/22.
Nausea, dieahhrea, chest discomfort, I was admitted to hospital because of a cardiac event . I continued to have pretty severe dieahhrea for the next 9 days. I went back saw my primary care doctor and gastroenterologist 10/15/2021 , no results back yet on breath test and blood panels.
Contracted Covid-19 on 10/24/20 from a family member who contracted it through their workplace.  Symptoms during active covid infection: - Low grade fever (topped ~ 102) - Body/muscle aches - Nausea/GI issues - ?Brain Fog? - 100% loss of smell and taste - Fatigue/Exhaustion - Sinus Congestion - Skin sensitivity Quarantined for 14 days and majority of symptoms were no longer present.   Over the next 4 months many symptoms resolved themselves while others remained present, and new symptoms became present.   It was determined by my primary healthcare providers that I am a ?long hauler?.  Symptoms remaining: - ?Brain Fog? - Fatigue/Exhaustion - Heart skipping a beat or fluttering - Feeling of ?thick blood? or low-oxygenated blood - Feeling faint/weak New Symptoms: - Unconscious deep breaths every 5-10 minutes - Difficulty swallowing/choking on non-food and non-drink swallows - Tightness in chest (usually relieved immediately by a large amount of water) - Feeling of a racing heart/skipping beats - Sinus congestion to the point of diminished hearing and ?popping? of ears - Anxiety while in public - Depression - Dry eyes/painful discharge from eyes   Received 1st  dose of Pfizer vaccine (ER8735) on 4/20/21 @ Pharmacy Received 2nd dose of Pfizer vaccine (EW0179) on 5/11/21 @ Pharmacy Effects 2+weeks after 2nd dose:   - Vertigo/Dizziness (far worse than prior to vaccine) - Tightness in chest (far worse than prior to vaccine) - ?Brain Fog? (far worse than prior to vaccine) - Fatigue/Exhaustion (fluctuates daily, in general far worse than prior to vaccine) - Intense need for hydration without the instinct of thirst - Perceived inability to regulate body temperature (often feeling hot while not hot or cold while not cold).   Sweating only in hands/feet. - Paranoia/anxiety/depression - Adverse reaction to extended sun exposure
Vials were expired; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vials were expired) in an 89-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 006C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 30-Nov-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 30-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Vials were expired). On 30-Nov-2021, EXPIRED PRODUCT ADMINISTERED (Vials were expired) had resolved. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were provided. No treatment medications were reported.  All patients were monitored for at least 15 minutes after the injection with no adverse events reported.
Headache, chills, low grade fever, muscle aches, injection site pain, lymph node pain
This spontaneous report as received from a physician refers to a 32 days old patient. On 26-NOV-2012 the patient was vaccinated with the first dose of ROTATEQ (lot # not reported). No adverse event was reported. It was unspecified whether the patient sought for medical attention. The outcome was unknown. Additional information has been requested.
This spontaneous report was received from a Licensed Practical Nurse referring multiple unspecified patients of unknown age and genders whom on unknown dates, received unspecified dose of improperly stored GARDASIL (lot #, doses, route and sites of administration not reported). This is one of 8 reports from the same source. No additional information provided. Additional information has been requested.
1/18/21, red and irritated, didn't feel anything.  This morning 1/20/21 was inflamed, the area of the vaccine is red, irritated and size of her fist.  From the area of the vaccine to her forearm, numb/tingling feeling.  No treatment.  Symptoms persist
This literature market report was received from an author. Abstract: Studies assessing the economic burden of a mumps outbreak in a highly vaccinated population are limited. A mumps investigation was conducted in an affected village with a highly vaccinated population. To understand the epidemiology, standardized mumps case definition and active surveillance were used to identify mumps cases. In addition, an economic assessment of a combined outbreak investigation and third dose MMR vaccine intervention was performed; estimated by retrospectively evaluating public health response-related activities including use of a third dose of MMR vaccine. From 24-SEP-2009 through 15-JUN-2010, 790 mumps cases were reported-64% were male and highest attack rate was among 11-17 year age group (99.1 cases per 1000 individuals). Of the 658 cases with known vaccination history, 83.6% had documentation of 2 doses of mumps containing vaccine. No deaths were reported. The 2 major exposure settings were schools (71.8%) and households (22.5%). Mumps cases were classified according to the 2008 mumps definition of the Epidemiologists. A clinical case was defined as an illness with acute onset of the parotitis, lasting at least 2 days, and without apparent cause. Clinically compatible illness was defined as that which may present as aseptic meningitis, encephalitis, hearing loss, orchitis, oophoritis, parotitis, or other salivary gland swelling, mastitis or pancreatitis. Laboratory confirmation included isolation of mumps virus from clinical specimen, or detection of mumps nucleic acid, or detection of mumps IgM antibody, or demonstration of a 4-fold increase in mumps IgG antibody titer. Mumps cases were then classified epidemiologically. A probable case was defined as that which meets the clinical case definition without laboratory confirmation and was epidemiologically linked to a clinically compatible case. A confirmed case was defined as a case that met the clinical case definition or had clinically compatible illness, and was either laboratory confirmed or was epidemiologically linked to a confirmed case. This report refers to the 15 case-patients with documented 1 doses of MMR (manufacturer unknown) vaccine, 27 (15%) and on an unknown date the patients developed parotitis. The outcome of event was unknown. The reporter considered events to be related to MMR (manufacturer unknown). This is one of the several reports with literature linked. Additional information has been requested.
PATIENT HAD INJECTION AND HAD NO PROBLEMS WAS RELEASED THEN RETURNED WITHIN 30 MINS STATING SHE FELT LIKE HER TONGUE WAS SWELLING. PATIENT WAS REASSESED AND OBSERVED FOR ADDITIONAL 15 MINS AND STATES FEELS FINE. PATIENT RELEASED AGAIN.
VACCINE STORED AT INAPPROPRIATE CONDITION BEFORE ADMINISTRATION; This spontaneous report received from a health care professional concerned a 37 year old male. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 20321A, and batch number: 20321A expiry: 23-JUN-2021) dose was not reported, administered on 03-MAY-2021 11:17 for prophylactic vaccination. No concomitant medications were reported.  On 03-MAY-2021, the subject experienced vaccine stored at inappropriate condition before administration. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of vaccine stored at inappropriate condition before administration was not reported. This report was non-serious. This case, from the same reporter is linked to.
Pt returned to clinic approx 48 hours after injection with large red inflamed hot area measuring approx. 3" x 4" around site of DTaP injection. Pt did show a slight limp.
Patient admitted to hospital on 4/25/2021 for trauma s/p motorcycle accident. No COVID symptoms. Patient stated that he had COVID in January 2021 and has since received both COVID vaccinations. Tested positive for COVID and Flu A via point of care antigen test on 4/25/2021.
pt recv vax & 10 days p/vax pt exp a generalized, maculopapular rash; No further details were provided;
This spontaneous report was received from a consumer concerning his approximately 84 year old father in-law with no drug reactions/allergies. The medical history of the patient included 2 replacements of valves in his heart and a pacemaker. On 18-JUN-2012, the patient was vaccinated with a dose of ZOSTAVAX (lot number and expiry date were 672608/1715AA and 02-FEB-2013 respectively) (dose and route unspecified). Concomitant medication included COUMADIN. On 15-DEC-2012, the patient experienced transverse myelitis. Approximately on 26-DEC-2012 (for the last 2 weeks), he experienced extreme pain and is now paralyzed from the waist down. He was admitted to the Medical Center since 01-JAN-2013. He was treated with an unspecified medication to boost his blood pressure. On an unknown date, computerized tomography scans with dye and unspecified blood test were performed. The outcomes of all the events were reported as not resolved. The relatedness for all the events was unknown for ZOSTAVAX. Additional information has been requested.
1st dose Aug 7th 2022, 2nd on Sep 23rd 2022; This case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too short in a 22-year-old patient who received HAV (Havrix) for prophylaxis.   Concurrent medical conditions included immunocompromised. Concomitant products included HEPATITIS A VACCINE (HAVRIX).   On 23rd September 2022, the patient received the 2nd dose of Havrix. On 23rd September 2022, unknown after receiving Havrix, the patient experienced drug dose administration interval too short. On an unknown date, the outcome of the drug dose administration interval too short was unknown.   Additional Information: GSK Receipt Date: 26-SEP-2022 Reporter's comment: Pharmacist reported that the patient received a 1st dose of Havrix on 7th August 2022 and 2nd dose on 23rd September 2022. The vaccine administration facility was the same as primary reporter. The reporter did not consent to follow-up. Additional Supportive Information: The patient received 2nd dose of Havrix earlier than the recommended interval, which led to shortening of vaccination schedule.
Lymphadenopathy- Posterior cervical.  Enlarged one day after first dose of vaccine,  Improved over time, but then worsened again after second dose which was given in the same arm on 6/3/2021.
pt recvd vax & 1-2 days later devel a large red, warm area around the site of inject, which extended below the elbow to the upper forearm; pt's lymph nodes were palpable;
On 10/21/10 client came to clinic to report that about 4 hours after "flu shot" she started to have vision concern blurry, eyes red/felt like 'sand in tears' then started to have difficulty breathing and chest pain. Went to local Hospital Emergency Rm -> admitted 10/7 -> ICU 3 days then discharged 10/11/10.
It has been greater than 42 days since she has had the first dose; It has been greater than 42 days since she has had the first dose; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (It has been greater than 42 days since she has had the first dose) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (It has been greater than 42 days since she has had the first dose) in a 78-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011a21a) for COVID-19 vaccination.     No Medical History information was reported.    On 26-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form(s). On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (It has been greater than 42 days since she has had the first dose) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (It has been greater than 42 days since she has had the first dose). At the time of the report, PRODUCT DOSE OMISSION ISSUE (It has been greater than 42 days since she has had the first dose) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (It has been greater than 42 days since she has had the first dose) outcome was unknown. Not Provided      mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was withdrawn on an unknown date.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No  concomitant medical  provided by the reporter. No treatment medication provided by the reporter.
Rapid heart rate, feeling of shortness of breathe  and chest pain for approx 20 days after booster.  Not terrible but concerning.  My resting heart rate was 20 beats higherrhan my normal resting rate.  It slowly declined over the next 20  to 30 days, where it was more in my normal range.  I did not seek medical care until approx 2.5 weeks had past.   Saw NP at Health Clinic.  She did a EKG which was fine. Ordered a echogram,  but with local scheduling it will be May 2022 before I can  get one.  Symptoms subsided and feel ok.  Without Echo cannot see heart.
This spontaneous report was received from an unspecified reporter referring to an unspecified number of patients of unknown age and gender. Information about the patients' medical histories and concurrent conditions was not provided. On an unknown date, the patients were vaccinated with doses of GARDASIL (administration routes, lot numbers and expiration dates were not provided). No concomitant therapies were reported. On unknown dates, the patients experienced unspecified adverse events. The outcomes of these adverse events were unknown. The reporter did not provide a causality assessment between the events and therapy with GARDASIL. Additional information is not expected, since the reporter can not be contacted.
Fever; chills; headache; fatigue; injection site pain; This is a spontaneous report from a contactable physician (patient). A 26-year-old male patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, lot/batch number and expiration date not available), intramuscularly on 23Dec2020 at 12:15 PM on Left arm at single dose for COVID-19 immunization in hospital. The patient medical history included asthma and previously COVID+, prior to vaccination, patient was diagnosed with COVID-19. No known allergy, no allergies to medications, food, or other products. Concomitant medications included salbutamol (ALBUTEROL), montelukast and loratadine. Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient experienced fever, chills, headache, fatigue, injection site pain; lasted approximately 24 hours on 24Dec2020 at 12:00 AM. Since the vaccination, patient had not been tested for COVID-19. Therapeutic measures were taken as result of the events included Ibuprofen. The outcome of the events was recovered in Dec2020. The report was reported as non-serious, with seriousness criteria-Results in death: No; Life threatening: No; Caused/prolonged hospitalization: No; Disabling/Incapacitating: No; Congenital anomaly/birth defect: No.  Information on the lot/batch number has been requested.
pain in shoulders & neck (arthritic type pain) a day or 2 p/vax cont w/o relief to date;
Initial report received from a health care professional on 24 November 2010. A female patient (age not reported) received on 20 November 2010 a left arm injection (route not provided) of FLUZONE, lot number U3631AA. The patient had no known allergies and her medical history was not reported. The patient's concomitant medications were FOSAMAX, tramadol, budesonide and SYMBICORT, and methocarbamol. On 24 November 2010, the patient reported experiencing fever, chills, nausea, runny nose, sneezing, coughing and headache. The outcome was reported as unknown. Follow-up information was received from the health care professional on 31 January 2011. The patient was 68 years old, had not received any other vaccines within 4 weeks of 20 November 2010. The FLUZONE HIGH-DOSE was given intramuscularly. The patient recovered on an unspecified date. Documents held by sender: None.
Hives noticed by parent approx 18hrs p/inject arms, face, legs; tx DPH;
Bad headache, mild fever and chills, intense body aches, arm/arm pit pain near injection site, very tired.